The content on this site is intended for healthcare professionals only
Prof David Cameron talks to ecancertv at EBCC 9 about the key messages for practising doctors from the meeting.
He covers radiotherapy post mastectomy, how genetic testing may improve selection of women with ER breast cancer for ten rather than five years of hormonal therapy, and gives his opinion on the ongoing screening debate.
View all content from this conference here
ESMO 2024: Optimising the personalisation of prostate cancer treatment
ERBB2 amplifications across sex, race, and cancer types studied to guide HER2 therapies
SABCS 2023: Latest breast cancer diagnostics guidelines
Genomic testing: Awareness and effective communication between healthcare professionals and patients
PHERGain trial ID's early breast cancer cases that benefit from dual HER2 blockade without chemo
The advantages of IORT for early breast cancer treatment
Neo-adjuvant therapy for different cancers in the Philippines
The pros and cons of breast IORT and ultra hypofractionation (FR)
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer
